Free Trial

Promising Medical Stocks Worth Watching - April 25th

Eli Lilly and Company logo with Medical background
Image from MarketBeat Media, LLC.

Key Points

  • MarketBeat's screener flagged Eli Lilly (LLY), UnitedHealth Group (UNH) and AbbVie (ABBV) as the top Medical stocks by dollar trading volume in recent days, indicating heightened investor interest and liquidity.
  • Eli Lilly stands out for its diabetes and obesity franchise (Jardiance, Mounjaro, Trulicity, Zepbound) and a strategic push that includes a reported $10 billion bet on AI and neuroscience to fuel future growth.
  • UnitedHealth is a diversified health-care operator across UnitedHealthcare and Optum segments providing insurance and services to multiple populations, while AbbVie depends on blockbusters like Humira, Skyrizi and Rinvoq plus oncology drugs, making both firms sensitive to clinical, regulatory and reimbursement developments.
  • Five stocks we like better than Eli Lilly and Company.

Eli Lilly and Company, UnitedHealth Group, and AbbVie are the three Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares of publicly traded companies involved in healthcare — including pharmaceutical and biotechnology firms, medical device makers, diagnostic and laboratory companies, hospitals and clinics, and health-related technology or service providers. Investors in medical stocks pay particular attention to factors like clinical trial results, regulatory approvals, patent protection, and reimbursement policies, which can create both significant volatility and long-term growth opportunities. These companies had the highest dollar trading volume of any Medical stocks within the last several days.

Eli Lilly and Company (LLY)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Read Our Latest Research Report on LLY

UnitedHealth Group (UNH)

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage.

Read Our Latest Research Report on UNH

AbbVie (ABBV)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

Read Our Latest Research Report on ABBV

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Eli Lilly and Company Right Now?

Before you consider Eli Lilly and Company, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.

While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Related Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines